Journal of Pain
August 1, 2026
Jon G. Dean, Ethan Hurwitz, T. Furnish et al.
Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classical serotonergic psychedelic drug, can alleviate various treatment-resistant disorders but has scantly been investigated for chronic pain. This placebo-controlled, double-blind, randomized clinical pilot trial (NCT05224336) tested the feasibility, tolerability, and preliminary...
Topics in Cognitive Science
May 26, 2026
Ethan Hurwitz, Jon G. Dean, Caren M. Walker
Psychedelic drugs have shown promise as a novel therapeutic for a variety of health conditions, yet the mechanisms underlying their clinical benefits remain unclear. A leading hypothesis suggests that psychedelics may enhance cognitive flexibility, a trait impaired in many of these conditions. While existing data from self-report and qualitative-interview studies support this hypothesis, data...
PLoS One
August 24, 2022
Mary M. Sweeney, Sandeep M. Nayak, Ethan Hurwitz et al.
60 citations
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by...
Journal of psychopharmacology (Oxford, England)
September 1, 2020
Alan K. Davis, John Clifton, Eric G Weaver et al.
144 citations
Experiences of having an encounter with seemingly autonomous entities are sometimes reported after inhaling N,N-dimethyltryptamine. The study characterized the subjective phenomena, interpretation, and persisting changes that people attribute to N,N-dimethyltryptamine-occasioned entity encounter experiences. Two thousand, five hundred and sixty-one individuals (mean age 32 years; 77% male)...
PLoS One
April 23, 2019
Roland R. Griffiths, Ethan Hurwitz, Alan K. Davis et al.
249 citations
Naturally occurring and psychedelic drug-occasioned experiences interpreted as personal encounters with God are well described but have not been systematically compared. In this study, five groups of individuals participated in an online survey with detailed questions characterizing the subjective phenomena, interpretation, and persisting changes attributed to their single most memorable God...
Psychopharmacology
October 1, 2018
Frederick S. Barrett, Theresa M. Carbonaro, Ethan Hurwitz et al.
109 citations
Classic psychedelics (serotonin 2A receptor agonists) and dissociative hallucinogens (NMDA receptor antagonists), though differing in pharmacology, may share neuropsychological effects. These drugs, however, have undergone limited direct comparison. This report presents data from a double-blind, placebo-controlled within-subjects study comparing the neuropsychological effects of multiple doses...
Psychopharmacology
February 1, 2018
Theresa M. Carbonaro, Matthew W Johnson, Ethan Hurwitz et al.
139 citations
Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and...